{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T19:10:11Z","timestamp":1793214611628,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,12,3]],"date-time":"2018-12-03T00:00:00Z","timestamp":1543795200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"NIH\/NIAMSNIH\/NIAMS (USA)","award":["5 T32 AR007279-39"],"award-info":[{"award-number":["5 T32 AR007279-39"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology Case Reports"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.ajoc.2018.12.001","type":"journal-article","created":{"date-parts":[[2018,12,4]],"date-time":"2018-12-04T12:41:00Z","timestamp":1543927260000},"page":"53-55","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":121,"special_numbering":"C","title":["Tofacitinib for refractory uveitis and scleritis"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8724-3176","authenticated-orcid":false,"given":"Michael A.","family":"Paley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Humeyra","family":"Karacal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Kumar","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd P.","family":"Margolis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan J.","family":"Miner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajoc.2018.12.001_bib1","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.survophthal.2005.04.003","article-title":"Acute anterior uveitis and HLA-B27","volume":"50","author":"Chang","year":"2005","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.ajoc.2018.12.001_bib2","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1586\/1744666X.2016.1171713","article-title":"Diagnosis and management of non-infectious immune-mediated scleritis: current status and future prospects","volume":"12","author":"Oray","year":"2016","journal-title":"Expet Rev Clin Immunol"},{"key":"10.1016\/j.ajoc.2018.12.001_bib3","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMoa1509852","article-title":"Adalimumab in patients with active noninfectious uveitis","volume":"375","author":"Jaffe","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajoc.2018.12.001_bib4","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0140-6736(16)31339-3","article-title":"Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial","volume":"388","author":"Nguyen","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ajoc.2018.12.001_bib5","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa1109071","article-title":"Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis","volume":"367","author":"Fleischmann","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajoc.2018.12.001_bib6","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJMoa1112072","article-title":"Tofacitinib or adalimumab versus placebo in rheumatoid arthritis","volume":"367","author":"van Vollenhoven","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajoc.2018.12.001_bib7","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","article-title":"Tofacitinib or adalimumab versus placebo for psoriatic arthritis","volume":"377","author":"Mease","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajoc.2018.12.001_bib8","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajoc.2018.12.001_bib9","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.clinthera.2014.06.018","article-title":"Systematic review of tofacitinib: a New drug for the management of rheumatoid arthritis","volume":"36","author":"Kaur","year":"2014","journal-title":"Clin Therapeut"},{"key":"10.1016\/j.ajoc.2018.12.001_bib10","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3121\/cmr.4.4.294","article-title":"Cytokines and chemokines in uveitis: is there a correlation with clinical phenotype?","volume":"4","author":"Ooi","year":"2006","journal-title":"Clin Med Res"},{"key":"10.1016\/j.ajoc.2018.12.001_bib11","doi-asserted-by":"crossref","first-page":"543","DOI":"10.2174\/1566524015666150731100012","article-title":"Cytokine expression profile in aqueous humor and sera of patients with acute anterior uveitis","volume":"15","author":"Chen","year":"2015","journal-title":"Curr Mol Med"},{"key":"10.1016\/j.ajoc.2018.12.001_bib12","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1001\/jamaophthalmol.2015.5934","article-title":"Precision medicine: personalized proteomics for the diagnosis and treatment of idiopathic inflammatory disease","volume":"134","author":"Velez","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ajoc.2018.12.001_bib13","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.ajo.2009.06.003","article-title":"High-dose daclizumab for the treatment of juvenile idiopathic arthritis-associated active anterior uveitis","volume":"148","author":"Sen","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajoc.2018.12.001_bib14","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.jcjo.2011.06.008","article-title":"Long-term daclizumab therapy for the treatment of noninfectious ocular inflammatory disease","volume":"46","author":"Wroblewski","year":"2011","journal-title":"Can J Ophthalmol J Can D Ophtalmol"},{"key":"10.1016\/j.ajoc.2018.12.001_bib15","doi-asserted-by":"crossref","first-page":"E400","DOI":"10.1111\/aos.13015","article-title":"Outcome of tocilizumab treatment in refractory ocular inflammatory diseases","volume":"94","author":"Silpa-archa","year":"2016","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.ajoc.2018.12.001_bib16","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12527","article-title":"Successful ustekinumab treatment of noninfectious uveitis and concomitant severe psoriatic arthritis and plaque psoriasis","volume":"30","author":"Mugheddu","year":"2017","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.ajoc.2018.12.001_bib17","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","article-title":"Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial","volume":"390","author":"Fleischmann","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ajoc.2018.12.001_bib18","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2011.406","article-title":"Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up","volume":"305","author":"Bartelds","year":"2011","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.ajoc.2018.12.001_bib19","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/IAE.0b013e3181bcef3b","article-title":"Adverse events after intravitreal infliximab (Remicade)","volume":"30","author":"Giganti","year":"2010","journal-title":"Retina"},{"key":"10.1016\/j.ajoc.2018.12.001_bib20","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/IAE.0b013e3181eac7a6","article-title":"Intravitreal tumor necrosis factor inhibitors in the treatment of refractory diabetic macular edema: a pilot study from the Pan-American Collaborative Retina Study Group","volume":"31","author":"Wu","year":"2011","journal-title":"Retina"},{"key":"10.1016\/j.ajoc.2018.12.001_bib21","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.exer.2015.12.005","article-title":"Anti-inflammatory effect of topical administration of tofacitinib on corneal inflammation","volume":"145","author":"Sakimoto","year":"2016","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.ajoc.2018.12.001_bib22","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/j.ophtha.2012.03.017","article-title":"Immunomodulatory effect of the topical ophthalmic Janus kinase inhibitor tofacitinib (CP-690,550) in patients with dry eye disease","volume":"119","author":"Huang","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajoc.2018.12.001_bib23","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.ophtha.2012.01.028","article-title":"Tofacitinib (CP-690,550), a Janus kinase inhibitor for dry eye disease: results from a phase 1\/2 trial","volume":"119","author":"Liew","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajoc.2018.12.001_bib24","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","article-title":"Baricitinib in patients with refractory rheumatoid arthritis","volume":"374","author":"Genovese","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajoc.2018.12.001_bib25","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus placebo or adalimumab in rheumatoid arthritis","volume":"376","author":"Taylor","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajoc.2018.12.001_bib26","doi-asserted-by":"crossref","DOI":"10.1001\/jamaophthalmol.2018.3789","article-title":"Treatment of mucous membrane pemphigoid with Janus kinase inhibitor baricitinib","author":"Sarny","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ajoc.2018.12.001_bib27","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/annrheumdis-2016-210322","article-title":"Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"}],"container-title":["American Journal of Ophthalmology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451993618303402?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451993618303402?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T14:56:34Z","timestamp":1762527394000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2451993618303402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":27,"alternative-id":["S2451993618303402"],"URL":"https:\/\/doi.org\/10.1016\/j.ajoc.2018.12.001","relation":{},"ISSN":["2451-9936"],"issn-type":[{"value":"2451-9936","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tofacitinib for refractory uveitis and scleritis","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajoc.2018.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}